Identification of key genes and immune infiltration in multiple myeloma by bioinformatics analysis

References

• Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015;385(9983):2197–2208. doi:10.1016/S0140-6736(14)60493-1
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125(20):3049–3058. doi:10.1182/blood-2014-11-568881
   PubMed Web of Science ®Google Scholar
• Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22(22):5428–5433. doi:10.1158/1078-0432.CCR-16-0866
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962. doi:10.1182/blood-2016-01-631200
   PubMed Web of Science ®Google Scholar
• Yang J, Wang F, Chen B. HLA-DPA1 gene is a potential predictor with prognostic values in multiple myeloma. BMC Cancer. 2020;20(1):915. doi:10.1186/s12885-020-07393-0
   PubMed Web of Science ®Google Scholar
• Peng Y, Wu D, Li F, et al. Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis. Cancer Cell Int. 2020;20:262. doi:10.1186/s12935-020-01355-z
   PubMed Web of Science ®Google Scholar
• Chaussabel D, Rinchai D. Using ‘collective omics data’ for biomedical research training. Immunology. 2018;155(1):18–23. doi:10.1111/imm.12944
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Kikuchi J. Molecular pathogenesis of multiple myeloma. Int J Clin Oncol. 2015;20(3):413–422. doi:10.1007/s10147-015-0837-0
   PubMed Web of Science ®Google Scholar
• Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. Br Med J. 2020;370:m3176. doi:10.1136/bmj.m3176
   PubMedGoogle Scholar
• Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71–84. doi:10.1038/s41571-020-0427-6
   PubMed Web of Science ®Google Scholar
• Gao H, Wang H, Yang W. Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis. Int J Hematol. 2017;106(1):99–107. doi:10.1007/s12185-017-2216-2
   PubMed Web of Science ®Google Scholar
• Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985–1005. doi:10.1038/s41375-020-0734-z
   PubMed Web of Science ®Google Scholar
• Xia B, Wang X, Yang R, et al. Epstein-Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma. Biosci Rep. 2019;39(10):1–9. doi:10.1042/BSR20190284
   Google Scholar
• Park GB, Chung YH, Jeong JY, et al. A p110delta-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-kappaB. Int J Oncol. 2017;50(5):1711–1720. doi:10.3892/ijo.2017.3923
   PubMed Web of Science ®Google Scholar
• Tarhriz V, Bandehpour M, Dastmalchi S, et al. Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol. 2019;234(3):2134–2142. doi:10.1002/jcp.27581
   PubMed Web of Science ®Google Scholar
• Altevogt P, Sammar M, Huser L, et al. Novel insights into the function of CD24: a driving force in cancer. Int J Cancer. 2021;148(3):546–559. doi:10.1002/ijc.33249
   PubMed Web of Science ®Google Scholar
• Ni YH, Zhao X, Wang W. CD24, a review of its role in tumor diagnosis, progression and therapy. Curr Gene Ther. 2020;20(2):109–126. doi:10.2174/1566523220666200623170738
   PubMed Web of Science ®Google Scholar
• Tanaka T, Terai Y, Kogata Y, et al. CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer. Oncol Rep. 2015;34(5):2282–2288. doi:10.3892/or.2015.4257
   PubMed Web of Science ®Google Scholar
• Eyvazi S, Kazemi B, Dastmalchi S, et al. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy. Curr Cancer Drug Targets. 2018;18(4):328–336. doi:10.2174/1570163814666170818125036
   PubMed Web of Science ®Google Scholar
• Barkal AA, Brewer RE, Markovic M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392–396. doi:10.1038/s41586-019-1456-0
   PubMed Web of Science ®Google Scholar
• Bradley CA. CD24 – a novel ‘don’t eat me’ signal. Nat Rev Drug Discov. 2019;18(10):747. doi:10.1038/d41573-019-00146-0
   PubMed Web of Science ®Google Scholar
• Mensah FFK, Armstrong CW, Reddy V, et al. CD24 expression and B cell maturation shows a novel link with energy metabolism: potential implications for patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front Immunol. 2018;9:2421. doi:10.3389/fimmu.2018.02421
   PubMed Web of Science ®Google Scholar
• Gilad N, Zukerman H, Pick M, et al. The role of CD24 in multiple myeloma tumorigenicity and effects of the microenvironment on its expression. Oncotarget. 2019;10(52):5480–5491. doi:10.18632/oncotarget.27190
   PubMedGoogle Scholar
• Rheinlander A, Schraven B, Bommhardt U. CD45 in human physiology and clinical medicine. Immunol Lett. 2018;196:22–32. doi:10.1016/j.imlet.2018.01.009
   PubMed Web of Science ®Google Scholar
• Bottero V, Santiago JA, Potashkin JA. PTPRC expression in blood is downregulated in Parkinson’s and progressive supranuclear palsy disorders. J Parkinsons Dis. 2018;8(4):529–537. doi:10.3233/JPD-181391
   PubMedGoogle Scholar
• Zhang Y, Wang F, Ning N, et al. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer. Int J Cancer. 2015;136(5):1228–1233. doi:10.1002/ijc.29070
   PubMed Web of Science ®Google Scholar
• Perron M, Saragovi HU. Inhibition of CD45 phosphatase activity induces cell cycle arrest and apoptosis of CD45(+) lymphoid tumors ex vivo and in vivo. Mol Pharmacol. 2018;93(6):575–580. doi:10.1124/mol.117.110908
   PubMed Web of Science ®Google Scholar
• Al Barashdi MA, Ali A, McMullin MF, et al. Protein tyrosine phosphatase receptor type C (PTPRC or CD45). J Clin Pathol. 2021;74(9):548–552. doi:10.1136/jclinpath-2020-206927
   PubMed Web of Science ®Google Scholar
• Saint-Paul L, Nguyen CH, Buffiere A, et al. CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts. Oncotarget. 2016;7(40):64785–64797. doi:10.18632/oncotarget.11622
   PubMedGoogle Scholar
• Gonsalves WI, Timm MM, Rajkumar SV, et al. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res. 2016;44:32–39. doi:10.1016/j.leukres.2016.03.003
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar SV, Kimlinger T, et al. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005;19(8):1466–1470. doi:10.1038/sj.leu.2403823
   PubMed Web of Science ®Google Scholar
• Abdollahi P, Kohn M, Borset M. Protein tyrosine phosphatases in multiple myeloma. Cancer Lett. 2021;501:105–113. doi:10.1016/j.canlet.2020.11.042
   PubMed Web of Science ®Google Scholar
• Alfarra H, Weir J, Grieve S, et al. Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy. Front Immunol. 2020;11:575609. doi:10.3389/fimmu.2020.575609
   PubMed Web of Science ®Google Scholar
• Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105(1):1–8. doi:10.1111/cas.12314
   PubMed Web of Science ®Google Scholar
• Zheng Y, Cai Z, Wang S, et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood. 2009;114(17):3625–3628. doi:10.1182/blood-2009-05-220285
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA. 2002;99(20):13009–13013. doi:10.1073/pnas.202491499
   PubMed Web of Science ®Google Scholar
• Guillerey C, Nakamura K, Vuckovic S, et al. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies. Cell Mol Life Sci. 2016;73(8):1569–1589. doi:10.1007/s00018-016-2135-z
   PubMed Web of Science ®Google Scholar